Journal of Endocrinological Investigation

, Volume 42, Issue 1, pp 7–17 | Cite as

Oxysterol species: reliable markers of oxidative stress in diabetes mellitus

  • A. Samadi
  • A. Gurlek
  • S. N. Sendur
  • S. Karahan
  • F. Akbiyik
  • I. LayEmail author
Original Article



To assess the plasma oxysterol species 7-ketocholesterol (7-Kchol) and cholestane-3β,5α,6β-triol (chol-triol) as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus (DM).


In total, 26 type 1 and 80 type 2 diabetes patients, along with 205 age- and gender-matched healthy controls, were included in this study. Oxysterols were quantified by liquid chromatography coupled with tandem mass spectrometry and N,N-dimethylglycine derivatization. Correlations between oxysterols and clinical/biochemical characteristics of the diabetes patients, and factors affecting 7-Kchol and chol-triol, were also determined.


Plasma 7-Kchol and chol-triol levels were significantly higher in type 1 and type 2 diabetes patients compared to healthy controls (P < 0.001). Significant positive correlations were observed between oxysterol levels and levels of glycated hemoglobin (HbA1c), glucose, serum total cholesterol, low-density lipoprotein, very-low-density lipoprotein, and triglycerides, as well as the number of coronary risk factors. Statins, oral hypoglycemic agents, and antihypertensive agents reduced the levels of oxysterols in type 2 diabetes patients. Statin use, HbA1c levels, and the number of coronary risk factors accounted for 98.8% of the changes in 7-Kchol levels, and total cholesterol, smoking status, and the number of coronary risk factors accounted for 77.3% of the changes in chol-triol levels in type 2 diabetes patients.


Plasma oxysterol levels in DM, and particularly type 2 DM, may yield complementary information regarding oxidative stress for the clinical follow-up of diabetes patients, especially those with coronary risk factors.


Oxysterols Diabetes mellitus Oxidative stress LC–MS/MS Tandem mass spectrometry 


Author contributions

Conceived, designed the study IL, AG. Wrote the paper IL, AS. Evaluated the patients SNS, AG. Performed the experiments AS, IL. Analyzed the data SK, AS, IL, AG, SNS. Contributed reagents/materials IL, FA.


This study was supported by a grant from Hacettepe University Scientific Research Projects Coordination Unit (Project No: THD 201610908), Ankara, Turkey.

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval

The study protocol adhered to the Declaration of Helsinki Guidelines and was approved by the Ethics Committee of Hacettepe University (GO 15/662).

Informed consent

Informed consent was obtained from each study participant.


  1. 1.
    Rösen P, Nawroth P, King G, Möller W, Tritschler HJ, Packer L (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored byUNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17(3):189–212PubMedGoogle Scholar
  2. 2.
    Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070PubMedPubMedCentralGoogle Scholar
  3. 3.
    Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23(5):599–622PubMedGoogle Scholar
  4. 4.
    Inouye M, Mio T, Sumino K (1999) Glycated hemoglobin and lipid peroxidation in erythrocytes of diabetic patients. Metabolism 48(2):205–209PubMedGoogle Scholar
  5. 5.
    Iuliano L, Micheletta F, Natoli S, Corradini SG, Iappelli M, Elisei W, Giovannelli L, Violi F, Diczfalusy U (2003) Measurement of oxysterols and α-tocopherol in plasma and tissue samples as indices of oxidant stress status. Anal Biochem 312(2):217–223PubMedGoogle Scholar
  6. 6.
    Korade Z, Xu L, Mirnics K, Porter NA (2013) Lipid biomarkers of oxidative stress in a genetic mouse model of Smith-Lemli-Opitz syndrome. J Inherit Metab Dis 36(1):113–122PubMedGoogle Scholar
  7. 7.
    Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, Antonini TM, Antonini R, Diczfalusy U, Iuliano L (2007) Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radical Biol Med 42(5):698–705Google Scholar
  8. 8.
    Brown AJ, Jessup W (2009) Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 30(3):111–122PubMedGoogle Scholar
  9. 9.
    Iuliano L (2011) Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem Phys Lipid 164(6):457–468Google Scholar
  10. 10.
    Vaya J, Szuchman A, Tavori H, Aluf Y (2011) Oxysterols formation as a reflection of biochemical pathways: summary of in vitro and in vivo studies. Chem Phys Lipid 164(6):438–442Google Scholar
  11. 11.
    Chang YH, Abdalla DS, Sevanian A (1997) Characterization of cholesterol oxidation products formed by oxidative modification of low density lipoprotein. Free Radical Biol Med 23(2):202–214Google Scholar
  12. 12.
    Howard J, Ingold K (1968) Self-reaction of sec-butylperoxy radicals. Confirmation of the Russell mechanism. J Am Chem Soc 90(4):1056–1058Google Scholar
  13. 13.
    Larsson H, Böttiger Y, Iuliano L, Diczfalusy U (2007) In vivo interconversion of 7β-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress. Free Radical Biol Med 43(5):695–701Google Scholar
  14. 14.
    Miyoshi N, Iuliano L, Tomono S, Ohshima H (2014) Implications of cholesterol autoxidation products in the pathogenesis of inflammatory diseases. Biochem Biophys Res Commun 446(3):702–708PubMedGoogle Scholar
  15. 15.
    Zarrouk A, Vejux A, Mackrill J, O’Callaghan Y, Hammami M, O’Brien N, Lizard G (2014) Involvement of oxysterols in age-related diseases and ageing processes. Ageing Res Rev 18:148–162PubMedGoogle Scholar
  16. 16.
    Wang M, Long W, Li D, Wang D, Zhong Y, Mu D, Song J, Xia M (2017) Plasma 7-ketocholesterol levels and the risk of incident cardiovascular events. Heart 103(22):1788–1794PubMedGoogle Scholar
  17. 17.
    Deckert V, Persegol L, Viens L, Lizard G, Athias A, Lallemant C, Gambert P, Lagrost L (1997) Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 95(3):723–731PubMedGoogle Scholar
  18. 18.
    Rosa-Fernandes L, Maselli LM, Maeda NY, Palmisano G, Bydlowski SP (2017) Outside-in, inside-out: proteomic analysis of endothelial stress mediated by 7-ketocholesterol. Chem Phys Lipid 207:231–238Google Scholar
  19. 19.
    Jessup W, Brown AJ (2005) Novel routes for metabolism of 7-ketocholesterol. Rejuvenation Res 8(1):9–12PubMedGoogle Scholar
  20. 20.
    Ferderbar S, Pereira E, Apolinario E, Bertolami M, Faludi A, Monte O, Calliari L, Sales J, Gagliardi A, Xavier H (2007) Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes Metab Res Rev 23(1):35–42PubMedGoogle Scholar
  21. 21.
    Abo K, Mio T, Sumino K (2000) Comparative analysis of plasma and erythrocyte 7-ketocholesterol as a marker for oxidative stress in patients with diabetes mellitus. Clin Biochem 33(7):541–547PubMedGoogle Scholar
  22. 22.
    Yoshioka N, Adachi J, Ueno Y, Yoshida K-I (2005) Oxysterols increase in diabetic rats. Free Radical Res 39(3):299–304Google Scholar
  23. 23.
    Matsui H, Okumura K, Mukawa H, Hibino M, Toki Y, Ito T (1997) Increased oxysterol contents in diabetic rat hearts: their involvement in diabetic cardiomyopathy. Can J Cardiol 13(4):373–379PubMedGoogle Scholar
  24. 24.
    Endo K, Oyama T, Saiki A, Ban N, Ohira M, Koide N, Murano T, Watanabe H, Nishii M, Miura M (2008) Determination of serum 7-ketocholesterol concentrations and their relationships with coronary multiple risks in diabetes mellitus. Diabetes Res Clin Pract 80(1):63–68PubMedGoogle Scholar
  25. 25.
    Murakami H, Tamasawa N, Matsui J, Yasujima M, Suda T (2000) Plasma oxysterols and tocopherol in patients with diabetes mellitus and hyperlipidemia. Lipids 35(3):333–338PubMedGoogle Scholar
  26. 26.
    Szuchman A, Aviram M, Musa R, Khatib S, Vaya J (2008) Characterization of oxidative stress in blood from diabetic vs. hypercholesterolaemic patients, using a novel synthesized marker. Biomarkers 13(1):119–131PubMedGoogle Scholar
  27. 27.
    Association AD (2016) Standards of medical care in diabetes—2016 abridged for primary care providers. Clin Diabetes Publ Am Diabetes Assoc 34(1):3Google Scholar
  28. 28.
    Jiang X, Sidhu R, Porter FD, Yanjanin NM, Speak AO, te Vruchte DT, Platt FM, Fujiwara H, Scherrer DE, Zhang J (2011) A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J Lipid Res 52(7):1435–1445PubMedPubMedCentralGoogle Scholar
  29. 29.
    Polo G, Burlina A, Furlan F, Kolamunnage T, Cananzi M, Giordano L, Zaninotto M, Plebani M, Burlina A (2016) High level of oxysterols in neonatal cholestasis: a pitfall in analysis of biochemical markers for Niemann-Pick type C disease. Clin Chem Lab Med 54(7):1221–1229PubMedGoogle Scholar
  30. 30.
    Reunert J, Lotz-Havla A, Polo G, Kannenberg F, Fobker M, Griese M, Mengel E, Muntau A, Schnabel P, Sommerburg O (2015) Niemann-Pick type C-2 disease: identification by analysis of plasma cholestane-3β, 5α, 6β-triol and further insight into the clinical phenotype. JIMD Rep 23:17–26PubMedPubMedCentralGoogle Scholar
  31. 31.
    Meagher EA, FitzGerald GA (2000) Indices of lipid peroxidation in vivo: strengths and limitations. Free Radical Biol Med 28(12):1745–1750Google Scholar
  32. 32.
    Yeo HC, Helbock HJ, Chyu DW, Ames BN (1994) Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 220(2):391–396PubMedGoogle Scholar
  33. 33.
    Hultén LM, Lindmark H, Diczfalusy U, Björkhem I, Ottosson M, Liu Y, Bondjers G, Wiklund O (1996) Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J Clin Investig 97(2):461PubMedGoogle Scholar
  34. 34.
    Brown AJ, Dean RT, Jessup W (1996) Free and esterified oxysterol: formation during copper-oxidation of low density lipoprotein and uptake by macrophages. J Lipid Res 37(2):320–335PubMedGoogle Scholar
  35. 35.
    Smith LL (1996) Review of progress in sterol oxidations: 1987–1995. Lipids 31(5):453–487PubMedGoogle Scholar
  36. 36.
    Miyashita Y, Shirai K, Ito Y, Watanabe J, Urano Y, Murano T, Tomioka H (1997) Cytotoxicity of some oxysterols on human vascular smooth muscle cells was mediated by apoptosis. J Atheroscler Thromb 4(2):73–78PubMedGoogle Scholar
  37. 37.
    Sevanian A, Berliner J, Peterson H (1991) Uptake, metabolism, and cytotoxicity of isomeric cholesterol-5, 6-epoxides in rabbit aortic endothelial cells. J Lipid Res 32(1):147–155PubMedGoogle Scholar
  38. 38.
    Deckert V, Brunet A, Lantoine F, Lizard G, Millanvoye-van Brussel E, Monier S, Lagrost L, David-Dufilho M, Gambert P, Devynck M-A (1998) Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol 18(7):1054–1060PubMedGoogle Scholar
  39. 39.
    Tremblay-Franco M, Zerbinati C, Pacelli A, Palmaccio G, Lubrano C, Ducheix S, Guillou H, Iuliano L (2015) Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human. Steroids 99:287–292PubMedGoogle Scholar
  40. 40.
    Alkazemi D, Egeland G, Vaya J, Meltzer S, Kubow S (2008) Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J Clin Endocrinol Metab 93(11):4282–4289PubMedGoogle Scholar
  41. 41.
    Evans JL, Maddux BA, Goldfine ID (2005) The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 7(7–8):1040–1052PubMedGoogle Scholar
  42. 42.
    Boumhras M (2012) Evaluation de la toxicité de moules de 2 sites de la Cote Atlantique Marocaine (Jorf Lasfar et Oualidia) utilisées comme bioindicateurs de contamination: étude in vivo et in vitro sur des rats et des cellules β-pancréatiques murines (MIN-6). Ecotoxicologie. Thesis, Université de Bourgogne, FrancaisGoogle Scholar
  43. 43.
    Tanaka Y, Uchino H, Shimizu T, Yoshii H, Niwa M, Ohmura C, Mitsuhashi N, Onuma T, Kawamori R (1999) Effect of metformin on advanced glycation end product formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol 376(1):17–22PubMedGoogle Scholar
  44. 44.
    Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino R, Lauro R, Violi F, Di Mario U, Sanguigni V (2002) Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev 18(2):156–159PubMedGoogle Scholar
  45. 45.
    Kanigür-Sultuybek G, Güven M, Onaran İ, Tezcan V, Cenani A, Hatemi H (1995) The effect of metformin on insulin receptors and lipid peroxidation in alloxan and streptozotocin induced diabetes. J Basic Clin Physiol Pharmacol 6(3–4):271–280PubMedGoogle Scholar
  46. 46.
    Pavlović D, Kocić R, Kocić G, Jevtović T, Radenković S, Mikić D, Stojanović M, Djordjević P (2000) Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab 2(4):251–256PubMedGoogle Scholar
  47. 47.
    Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol J-P (2002) Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 40(4):611–617PubMedGoogle Scholar
  48. 48.
    Tomás M, Sentí M, García-Faria F, Vila J, Torrents A, Covas M, Marrugat J (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20(9):2113–2119PubMedGoogle Scholar
  49. 49.
    Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW (1999) Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33(1):234–241PubMedGoogle Scholar
  50. 50.
    Franzoni F, Quiñones-Galvan A, Regoli F, Ferrannini E, Galetta F (2003) A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 90(2):317–321PubMedGoogle Scholar
  51. 51.
    Guan J-Z, Murakami H, Yamato K, Tanabe J, Matsui J, Tamasawa N, Suda T (2004) Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1. J Atheroscler Thromb 11(2):56–61PubMedGoogle Scholar
  52. 52.
    Münzel T, Keaney JF (2001) Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation 104(13):1571–1574PubMedGoogle Scholar
  53. 53.
    Mol MJ, de Rijke YB, Demacker PN, Stalenhoef AF (1997) Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. Atherosclerosis 129(2):169–176PubMedGoogle Scholar
  54. 54.
    Eliasson B (2003) Cigarette smoking and diabetes. Prog Cardiovasc Dis 45(5):405–413PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2018

Authors and Affiliations

  1. 1.Department of Medical Biochemistry, Faculty of MedicineHacettepe UniversityAnkaraTurkey
  2. 2.Department of Internal Medicine, Endocrinology Unit, Faculty of MedicineHacettepe UniversityAnkaraTurkey
  3. 3.Department of Biostatistics, Faculty of MedicineHacettepe UniversityAnkaraTurkey
  4. 4.Clinical Pathology LaboratoryHacettepe University HospitalsAnkaraTurkey

Personalised recommendations